EU-GMP Chapter 1 has been in operation since 31 January 2013, and every other chapter of the EU-GMP guide hangs from it. On 3 September 2025, the European Commission opened consultation on its first major rewrite in more than a decade. If you're a Canadian Licensed Producer supplying the EU medical channel, this is the chapter an importer's auditor uses to decide whether your quality system is real or just a binder.
The EU-GMP Chapter 1 pharmaceutical quality system is a documented system, owned by senior management, that keeps product quality under control from supplier to shipment. In practice, it means a quality manual, periodic management review, an annual product quality review, quality risk management and root-cause investigations with CAPA effectiveness checks. Health Canada rules cover parts of this. Not all of it.
What the EU-GMP Chapter 1 pharmaceutical quality system requires
Chapter 1 ties together three ideas: quality management, Good Manufacturing Practice and quality risk management. The 2013 revision renamed the chapter and aligned it with ICH Q10, the international guideline on pharmaceutical quality systems. Medical cannabis flower entering the EU is handled as a medicinal product, so your quality system is judged by the same text a tablet manufacturer's is.
The 17 outcomes in paragraph 1.4
Paragraph 1.4 lists 17 things the quality system must ensure. For a flower producer, these six carry the most audit weight:
- Correct starting and packaging materials, with supplier selection, supplier monitoring and proof that each delivery came from the approved supply chain (item vi).
- Control of outsourced work such as contract testing and irradiation, covered in our guide to EU-GMP Chapter 7 outsourced activities (item vii).
- A state of control, built on monitoring of process performance and product quality (item viii).
- Prospective approval of planned changes, plus a check after implementation that nothing went wrong (items xii and xiii). Our article on cannabis change control under EU-GMP walks through the mechanics.
- Root cause analysis scaled to risk, with CAPA effectiveness monitored (item xiv).
- Regular self-inspection that tests whether the system works (item xvii).
Item xiv sets a high bar for human error. If you blame an operator, you have to justify it and show you didn't miss a process or system cause. A deviation closed as "operator retrained" with no system review will not survive an EU audit. The practical fixes are in our guide to cannabis deviation and CAPA management.
Senior management, management review and the quality manual
Paragraph 1.5 gives senior management the ultimate responsibility for an effective, adequately resourced quality system. Paragraph 1.6 requires periodic management review with senior management involved. Paragraph 1.7 requires the system to be defined and documented in a quality manual or equivalent that includes management responsibilities.
The common gap is a full SOP library with no document explaining how the SOPs connect. That connecting document is the quality manual. If your last management review has no minutes, no decisions and no senior signature, you aren't ready for an EU importer audit.
Product quality review and quality risk management
Paragraph 1.10 asks for a product quality review, normally every year, of all authorised products. That explicitly includes export-only products, which describes most EU-bound Canadian flower. The review covers at least 12 areas. They run from starting materials and failed batches to stability trends, complaints, recalls and the status of HVAC and other utilities. Our cannabis product quality review guide sets out each area.
Paragraphs 1.12 and 1.13 define quality risk management as a systematic process for assessing, controlling, communicating and reviewing risks to quality. The effort and documentation must match the level of risk. That proportionality clause is what lets a mid-sized LP run a lean system, provided the risk logic is written down.
How Chapter 1 compares with Health Canada Good Production Practices
Part 5 of the Cannabis Regulations sets the Good Production Practices every Canadian licence holder follows. They control the product well: sanitation, testing, storage and quality approval before sale. What they don't require is most of the management system Chapter 1 sits on.
| Chapter 1 element | EU-GMP Chapter 1 | Cannabis Regulations |
|---|---|---|
| Quality manual | Required (1.7) | No equivalent requirement |
| Senior management accountability | Ultimate responsibility for the system (1.5) | Responsible person who can bind the licence holder |
| Management review | Periodic, with senior management (1.6) | Not required |
| Product quality review | Normally annual, export-only included (1.10) | Not required |
| Quality risk management | Required, proportionate to risk (1.12 to 1.13) | Not required |
| Batch release | EU Qualified Person certifies each batch (1.4 xv) | Quality assurance person approves before sale |
The batch release row is where the two systems meet. Your quality assurance person signs off in Canada, then the importer's EU Qualified Person certifies the batch again. The QP's decision leans on your quality system, which is why the EU QP batch release process exposes Chapter 1 gaps quickly.
Health Canada GPP was written to control a product. Chapter 1 was written to control the system that makes it, and EU auditors test the system first.
What the 2025 draft revision of Chapter 1 changes
ICH Q9(R1), the revised guideline on quality risk management, was adopted in January 2023. Thirty-two months later, the draft Chapter 1 arrived to bring EU-GMP into line with it. The text was prepared by the EMA's GMP and GDP inspectors working group together with PIC/S, and the Commission's stakeholder consultation closed on 3 December 2025. At the time of writing, the 2013 text remains the version in operation, and the final revision is targeted for the fourth quarter of 2026 with a transition period expected.
Most of the draft is about risk. Seven new paragraphs cover risk-based decisions, how formal an assessment should be, and the subjectivity built into risk scoring. A new item 1.4(xviii) pairs knowledge management with risk management as an early warning system for quality and manufacturing problems.
The product quality review rules get sharper too. The draft explains when products can be grouped, asks for trend data from earlier reviews when few batches were made in 12 months, and sets minimum content for a year with no batches at all.
The draft also makes shortage prevention part of the quality system, treating supply interruption as a patient risk. For cannabis, the PQR change matters most. Cultivar rotation means many LPs make only a handful of batches of each cultivar a year, which is exactly the low-volume case the draft addresses. Grouping cultivars in one review will need a written scientific justification, not convenience. Build your PQR to the draft now and the final text won't force a rewrite in 2027.
The 5-step Chapter 1 build for Canadian LPs
This sequence turns Chapter 1 into a file an auditor can follow in one sitting. Run it before an importer audit or a remote documentation review.
1. Write a quality manual mapped to paragraph 1.4
List all 17 items and point each one to the SOP, record or role that delivers it. Items with no owner are your gap list.
2. Hold a minuted management review
Put senior management in the room, review deviations, CAPA status, complaints and audit results, and record decisions with owners and dates. A review with no decisions doesn't count.
3. Run a product quality review for each cultivar or justified group
Cover the 12 areas in paragraph 1.10 and keep trend data from earlier reviews. Low-volume cultivars are where the draft revision will look hardest.
4. Keep a living quality risk register
Score risks to flower quality and supply, record the reasoning, and link every major change to a risk assessment. Our guide to quality risk management under ICH Q9(R1) covers the scoring tools.
5. Close the loop with self-inspection
Audit the system against Chapter 1 once a year and feed findings into the next management review. The Chapter 9 self-inspection guide shows how to structure that audit.
AlphaLeaf is a Health Canada Licensed Producer growing indoor in Montreal, with refined genetics and hand-trimmed finishing on every batch. We hold export authorisation under the Cannabis Act. ISO-certified test data and full batch traceability sit behind each lot, so EU importers and their Qualified Persons get the quality-system evidence their audits ask for.
Want to see how our quality manual and management review records stand up to Chapter 1? Contact our team to request supplier documentation. Start with the quality manual.
Frequently Asked Questions
What is EU-GMP Chapter 1?
EU-GMP Chapter 1 is the Pharmaceutical Quality System chapter of the EU GMP Guide, in operation since 31 January 2013. It requires a documented quality system owned by senior management, covering GMP, quality control, an annual product quality review and quality risk management.
Does EU-GMP Chapter 1 apply to Canadian cannabis producers?
It applies once your flower enters the EU medical channel. The importer's Qualified Person must certify that each batch was made under GMP standards equivalent to the EU's, so your quality system is assessed against EU-GMP, including Chapter 1.
Is Health Canada GPP the same as an EU-GMP pharmaceutical quality system?
No. Good Production Practices under the Cannabis Regulations control sanitation, testing, storage and quality approval. They do not require a quality manual, management review, product quality review or formal quality risk management, which Chapter 1 does.
What should a quality manual contain under EU-GMP Chapter 1?
Paragraph 1.7 asks for a description of the quality management system, including management responsibilities. ICH Q10 adds the quality policy, the scope of the system, and how its processes link together.
How often is a product quality review required?
Paragraph 1.10 says product quality reviews should normally be conducted and documented annually, taking previous reviews into account. Export-only products are explicitly included, so EU-bound Canadian flower needs one.
When will the revised EU-GMP Chapter 1 apply?
The Commission's consultation on the draft closed on 3 December 2025, and the final text is targeted for the fourth quarter of 2026. A transition period is expected after publication, so the 2013 text applies until then.
